Recent advances in regulating the proliferation or maturation of human-induced pluripotent stem cell-derived cardiomyocytes

Stem Cell Research & Therapy

Review

Hao Yang¹  Yuan Yang¹  Fedir N. Kiskin¹  Joe Z. Zhang¹  Mengcheng Shen² 

[1] Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, 518132, Shenzhen, China;Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA;

关键词: Human-induced pluripotent stem cells;    Cardiac differentiation;    Cardiomyocytes;    Proliferation;    Maturation;   

DOI  :  10.1186/s13287-023-03470-w

 received in 2023-03-21, accepted in 2023-08-23,  发布年份 2023

来源: Springer

【 摘 要 】

In the last decade, human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM)-based cell therapy has drawn broad attention as a potential therapy for treating injured hearts. However, mass production of hiPSC-CMs remains challenging, limiting their translational potential in regenerative medicine. Therefore, multiple strategies including cell cycle regulators, small molecules, co-culture systems, and epigenetic modifiers have been used to improve the proliferation of hiPSC-CMs. On the other hand, the immaturity of these proliferative hiPSC-CMs could lead to lethal arrhythmias due to their limited ability to functionally couple with resident cardiomyocytes. To achieve functional maturity, numerous methods such as prolonged culture, biochemical or biophysical stimulation, in vivo transplantation, and 3D culture approaches have been employed. In this review, we summarize recent approaches used to promote hiPSC-CM proliferation, and thoroughly review recent advances in promoting hiPSC-CM maturation, which will serve as the foundation for large-scale production of mature hiPSC-CMs for future clinical applications.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 4